Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

NCT03443960 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: TNX-102 SL 5.6 mg
DRUG: Amrix 30 mg

Sponsor

Tonix Pharmaceuticals, Inc.